624,363 Shares in Personalis, Inc. $PSNL Bought by Next Century Growth Investors LLC

Next Century Growth Investors LLC acquired a new position in shares of Personalis, Inc. (NASDAQ:PSNL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 624,363 shares of the company’s stock, valued at approximately $4,970,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PSNL. Legal & General Group Plc bought a new position in Personalis during the second quarter worth about $30,000. International Assets Investment Management LLC bought a new position in Personalis during the fourth quarter worth about $31,000. BNP Paribas Financial Markets lifted its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after acquiring an additional 3,592 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in Personalis during the first quarter worth about $47,000. 61.91% of the stock is currently owned by institutional investors.

Insider Activity at Personalis

In related news, CFO Aaron Tachibana sold 40,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total transaction of $480,400.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,387,984.33. This represents a 16.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 80,091 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,799 shares of company stock valued at $2,031,692 over the last three months. Insiders own 4.20% of the company’s stock.

Personalis Stock Performance

PSNL opened at $9.59 on Monday. The business’s 50-day simple moving average is $7.55 and its 200 day simple moving average is $8.25. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $12.53. The firm has a market capitalization of $1.00 billion, a PE ratio of -9.40 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. On average, research analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PSNL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Morgan Stanley reduced their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC lifted their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, BTIG Research reduced their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.